H.R. 749 is intended to require the U.S. Food and Drug Administration to act upon applications for generic drugs within 180 days of being filed that are in short supply or when there are too few manufacturers on the market is being revised.
Some 83% of patients with chronic myelogenous leukemia taking Gleevec (imatinib) can live 10 years or longer, according to new data published in the New England Journal of Medicine, NBC News is reporting. The study looked at the original 1,100 patients in the Gleevec trial, though in the years since approval several generics have hit the market. The data shows the drug, which targets a CML-specific genetic mutation, has a 10-year survival rate of nearly 83%. (NBC News)
Clobetasol Propionate Topical Solution USP, 0.05% is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Twenty years ago this month, I put on what was then my “lucky” tie, this horrible, neon yellow number from Banana Republic — it wore more like a bad Hawaiian shirt than a tie — and I started a new job as senior editor for OTCs and natural health at Drug Store News. Sure, I have a lot less hair today than I did then, but I also have much better taste in ties.
Specialty and biotech medicines aimed at treating cancer, multiple sclerosis and rare diseases will dominate much of drug development in 2017 and beyond, one of the nation’s top specialty pharmacy providers concluded.